Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.panagrx.com
Number of Employees: -
Year Founded: 2014
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Panag Pharma Inc. develops bio pharmaceuticals and natural health products containing cannabis and other medicinal plant based elements. The company was founded in 2014 and is based in Halifax, Canada. As of May 1, 2019, Panag Pharma Inc. operates as a subsidiary of Tetra Bio-Pharma Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
No Key Professionals have been profiled.


Primary Industry Classification
Pharmaceuticals


Primary Office Location
Suite 1300 1969 Upper Water Street Purdy's Wharf Tower II | Halifax, NS | B3J 3R7 | Canada

Parent Company
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-06-2018
May-01-2019
Merger/Acquisition
Target
Panag Pharma Inc.
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)

20.84
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-10-2022
Client Announcements
Panag Pharma Inc. Announces Licensing Agreement with True North for Patented CBD Technology
Apr-27-2020
Product-Related Announcements
Tetra Bio-Pharma Adding a New Indication in the Development of PPP003
Jun-11-2019
Product-Related Announcements
Panag Pharma Inc. Completes Phase 3 Trial with Awaye™
May-09-2019
Product-Related Announcements
Panag Pharma Provides an Update on Recent Activities
May-02-2019
Product-Related Announcements
Panag Pharma Inc. Obtains Health Canada Authorization to Commence its First Veterinary Clinical Study

M&A Advisors
Borden Ladner Gervais LLP


Advisors
M&A Advisors
Borden Ladner Gervais LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Dec 16, 2019 05:40 AM
Panag Pharma Inc.
Panag Pharma Inc. - Company Report
Reports
11
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:37 AM
Panag Pharma Inc.
Panag Pharma Inc. - Company Report
Reports
11
Infinata, Inc.
Infinata Research
Jun 10, 2019 06:45 AM
Panag Pharma Inc.
Panag Pharma Inc. - Company Report
Reports
11
Infinata, Inc.
Infinata Research
Mar 11, 2019 04:55 AM
Panag Pharma Inc.
Panag Pharma Inc. - Company Report
Reports
10
Infinata, Inc.
Infinata Research
Dec 17, 2018 05:43 AM
Panag Pharma Inc.
Panag Pharma Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 24, 2018 04:59 AM
Panag Pharma Inc.
Panag Pharma Inc. - Company Report
Reports
7


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
PPP003 (Future), PPP004 (Future)


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Jul-18-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
267 KB
Jun-19-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
Short Form Prospectus (NI 44-101)
1 MB
Jun-11-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
221 KB
May-27-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
Management Proxy Materials
414 KB
May-09-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
301 KB
May-01-2019
Panag Pharma Inc.
SEDAR
News Releases
690 KB
Apr-18-2019
Panag Pharma Inc.
SEDAR
News Releases
201 KB
Mar-26-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
Management Proxy Materials
80 KB
Mar-26-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
Management Proxy Materials
433 KB
Mar-26-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
Management Proxy Materials
68 KB

Key Executives and Professionals Details
No Key Executives and Professionals exist.

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
